Navigation Links
Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man
Date:5/20/2013

New York, NY (PRWEB) May 20, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a South Dakota man who alleges that use of the diabetes drug medication Actos (pioglitazone) caused bladder cancer. The suit was filed on April 30, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-0888), where it is one of thousands of cases pending in the Actos multidistrict litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation. Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff began taking Actos in January 2009. He developed bladder cancer in May 2011, allegedly due to the side effects of Actos. At this time, he stopped taking the medication. The lawsuit alleges that the Defendants were aware that taking the diabetes drug could lead to an increased risk of bladder cancer, but failed to disclose this information to the Plaintiff, his doctor and other consumers. The Plaintiff is suing for extensive pain and suffering, severe emotional distress.

According to the U.S. Food and Drug Administration (FDA), taking Actos for one year may significantly increase your risk of bladder cancer. The safety label for Actos was updated in June 2011 to reflect this risk*. The warning was based on the results of an ongoing 10-year study by Kaiser Permanente. *(http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm)

Studies have continued to suggest that Actos can increase the risk of bladder cancer. For instance, the May 31, 2012 issue of the British Medical Journal** found that Actos users were twice as likely to develop bladder cancer after two years. In July 3, 2012, the Canadian Medical Association Journal*** found that patients taking the medication were 22 percent more likely to get bladder cancer. **(http://www.bmj.com/content/344/bmj.e3645) ***(http://www.cmaj.ca/content/early/2012/07/03/cmaj.112102)

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/actos-cancer-lawsuits/052013/prweb10751877.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Monterey Bay Nutraceuticals Now Taking Advance Orders Online
2. Garcinia Cambogia Select - A Miracle Weight Loss Supplement Taking the Industry by Storm; Exclusive News by Health Care Supplementz
3. University Finds that People Trade Off Healthy Habits Due to Time Constraints, Suggesting that Just Taking Supplements Like Prescopodene May Help With Weight Loss
4. Taking cholesterol-lowering drugs may also reduce the risk of dying from prostate cancer: Study
5. Multicenter study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib
6. MedMar Healing Center, Taking Clone Pre-Orders for High-Quality Medical Marijuana Strains
7. Poor Health Literacy Keeps Patients From Taking Meds
8. Diet Can Lower Blood Pressure As Much As Taking A Medication, From The March 2013 Harvard Men's Health Watch
9. First of its kind study in Canada looks at who is taking aspirin to prevent heart attack or stroke
10. Increasing Number of Doctors Recommend Taking Gene-Eden-VIR
11. Test-taking may improve learning in people of all ages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... The National Association of Chain ... in Puerto Rico. Radio messages set to debut on Monday, May 9, and ... about ways to protect themselves and their unborn children from the effects of ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President and CEO Ibraheem ... pharmaceutical industry conducts clinical trials. This month Ibs was named No. 20 on The ... he was honored as a Tech Disruptor by the Philadelphia Business Journal. , Stephanie ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... Bluvault's Integration Service, their latest implementation service offering for global clients of Coupa ... Appterra ). , Bluvault’s Integration Service is a key component in the ...
(Date:5/6/2016)... ... 06, 2016 , ... From May 4 to 6, EarQ and ... opportunity to learn more about Signia’s technology and the successful business and marketing techniques ... priority to see practices succeed in this highly competitive industry,” said Ed Keller, president ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing ... operated for over 35 years. Maintaining core values of exceptional customer service, quality work ... made them a leading name in San Diego plumbing, and other services including heating ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... , May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... of Directors declared a fiscal year 2016 third quarter ... percent increase over the amount paid a year ago. ... record as of the close of business on June 10, ...    Hill-Rom is a leading global medical technology ...
(Date:5/5/2016)... Ltd. today reported initial promising results in animal trials of its Zika vaccine candidates. ... ... ... ... Pubmed. The analysis identified the highest gene Replikin Counts in Zika history back to ...
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
Breaking Medicine Technology: